Cargando…

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

Simultaneous targeting of epidermal growth factor receptor (EGFR) and Met in cancer therapy is under pre-clinical and clinical evaluation. Here, we report the finding that treatment with EGFR inhibitors of various tumor cells, when stimulated with hepatocyte growth factor (HGF) and EGF, results in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castoldi, R, Ecker, V, Wiehle, L, Majety, M, Busl-Schuller, R, Asmussen, M, Nopora, A, Jucknischke, U, Osl, F, Kobold, S, Scheuer, W, Venturi, M, Klein, C, Niederfellner, G, Sustmann, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898114/ https://www.ncbi.nlm.nih.gov/pubmed/23812422 http://dx.doi.org/10.1038/onc.2013.245

Ejemplares similares

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012)

TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations
por: Castoldi, Raffaella, et al.
Publicado: (2016)

P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model
por: Kobold, S, et al.
Publicado: (2014)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
por: Patnaik, Amita, et al.
Publicado: (2018)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

The mechanism of action and biodistribution of a novel EGFR/VEGF bispecific fusion protein that exhibited superior antitumor activities
por: Deng, Lan, et al.
Publicado: (2023)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells
por: Soto-Gamez, Abel, et al.
Publicado: (2020)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer
por: Wang, Junxiong, et al.
Publicado: (2016)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
por: Kühl, Lennart, et al.
Publicado: (2023)

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
por: Jin, Junyeong, et al.
Publicado: (2018)

Involvement of lipid rafts in adhesion-induced activation of Met and EGFR
por: Lu, Ying-Che, et al.
Publicado: (2011)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
por: Fan, Fushun, et al.
Publicado: (2020)

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
por: Li, Li, et al.
Publicado: (2020)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
por: Mohan, Nishant, et al.
Publicado: (2022)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells
por: Pietraszek‐Gremplewicz, Katarzyna, et al.
Publicado: (2019)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications
por: Feldt, Susan L., et al.
Publicado: (2023)

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
por: Urbanska, Edyta M., et al.
Publicado: (2023)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
por: Zhang, Guangtao, et al.
Publicado: (2023)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Cigarette smoke enhances oncogene addiction to c‐MET and desensitizes EGFR‐expressing non‐small cell lung cancer to EGFR TKIs
por: Tu, Chih‐Yen, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
por: Jones, Rhys D.O., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_adfjsubb4o1t4t5bu2sakip8q9